SPIA
CLSD

Steward Partners Investment Advisory’s Clearside Biomedical CLSD Stock Holding History

Steward Partners Investment Advisory’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-733
Closed -$12.9K – 3589
2023
Q4 		$12.9K Hold
733
– – ﹤0.01% 2602
2023
Q3 		$9.57K Hold
733
– – ﹤0.01% 2615
2023
Q2 		$12.3K Hold
733
– – ﹤0.01% 2501
2023
Q1 		$11.4K Hold
733
– – ﹤0.01% 2495
2022
Q4 		$12.3K Buy
+733
New +$13.2K ﹤0.01% 2464

Other funds holding CLSD

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Steward Partners Investment Advisory's CLSD Position: Q1 2024 in Review

Steward Partners Investment Advisory sold out of Clearside Biomedical (CLSD) in Q1 2024, closing a stake of 733 shares — an estimated $12.9K sold.

Steward Partners Investment Advisory first reported a position in CLSD in Q4 2022 and held it in 5 quarters. The position peaked at $12.9K in Q4 2023. 51 funds tracked by Wall St. Rank hold CLSD as of Q1 2024.

  • Steward Partners Investment Advisory reported no remaining Clearside Biomedical position as of Q1 2024 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 733 Clearside Biomedical shares in Q1 2024, an estimated $12.9K.
  • Steward Partners Investment Advisory first reported a position in Clearside Biomedical in Q4 2022 and held it in 5 quarters.
  • Steward Partners Investment Advisory's Clearside Biomedical position peaked at $12.9K in Q4 2023.
  • 51 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2024.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2024, filed 15 May 2024.